July 16, 2019 — Boston, MA — QuartzBio, part of Precision for Medicine, today announced a significant expansion of its computational biology and multiomic data integration capabilities through the launch of a Boston-based office. The new office is one of many recent investments in Artificial Intelligence and computational biology expertise to cement its position as a leading solution for the integration, and analysis of biological data to support biomarker-guided drug development.
QuartzBio is accelerating its knowledge management, systems biology and mechanism-driven analytic capabilities to improve drug developers’ and translational researchers’ ability to make connections within the multiomic data ecosystems of drug discovery and development. With these expanded capabilities, QuartzBio will be able to better inform pre-clinical disease modeling and target pathway selection as well as response prediction and mechanism of action characterization. At present, the QuartzBio team has worked successfully with biomarker data from over 100 clinical trials and prior knowledge data sets.
In establishing the new office, QuartzBio welcomes industry leader Dr. Renee Deehan-Kenney as Vice President of Computational Biology, whose responsibility includes growing the existing QuartzBio presence in Boston as well leading a global computational biology and translational informatics team.